Department of Medicine

Medical Societies honor multiple Vanderbilt faculty

Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI).

MSA proclamation

A retired high school basketball coach from Murfreesboro was honored by the Tennessee State Senate on Thursday, March 21, for his efforts to shine a light on the rare disease that killed his wife six years ago.

From left, Wei Zheng, MD, PhD, Jae Jeong Yang, PhD, Danxia Yu, PhD, and colleagues are studying smoking patterns and associated deaths in Asian countries.

Asian nations in early tobacco epidemic: study

Asian countries are in the early stages of a tobacco smoking epidemic with habits mirroring those of the United States from past decades, setting the stage for a spike in future deaths from smoking-related diseases.

The Vanderbilt team studying histoplasmosis includes (front row, from left, Heidi Chen, PhD, Melinda Aldrich, PhD, MPH, (back row, from left) Stephen Deppen, PhD, Eric Grogan, MD, MPH, and Jeffrey Blume, PhD.

Team explores fungal infection quandary in lung cancer screenings

Serving a region that lies within the tobacco belt, clinicians at Vanderbilt Health face challenges distinguishing lung cancer from histoplasmosis, a fungal infection that creates cancer-mimicking lesions in the lungs.

Research by Robert Coffey, MD, left, Dennis Jeppesen, PhD, and colleagues has revealed a new way cells shed DNA into the bloodstream.

Discovery aids search for cancer biomarkers

A report by researchers at Vanderbilt University Medical Center has shattered conventional wisdom about how cells, including cancer cells, shed DNA into the bloodstream: they don’t do it by packaging the genetic material in tiny vesicles called exosomes.

From left, Benjamin Brown, Christine Lovly, MD, PhD, Yun-Kai Zhang, PhD, Jens Meiler, PhD, and colleagues are exploring new ways to understand resistance to targeted cancer therapy drugs.

Study reframes approach to targeted therapy resistance

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

1 74 75 76 77 78 124